## Amendments to the Specification

Please replace paragraph [0052] with the following paragraph:

[0052] For example, octapeptides (P<sub>4</sub>-P'<sub>4</sub>) for MMP 2 and MMP 9 have been identified (see Table 1), which octapeptides simulate the cleavage sequence of the collagen chain and are cleaved with particular efficiency by MMP 2 and 9 (in what follows, amino acids are abbreviated in accordance with the international three-letter code):

## Table 1:

Peptide

 $P_4 \quad P_3 \quad P_2 \quad P_1 \quad P'_1 \quad P'_2 \quad P'_3 \quad P'_4$ 

Gly-Pro-Leu-Gly--Ile-Ala-Gly-Gln [SEQ. ID No. 1]

Gly-Pro-Gln-Gly--Ile-Trp-Gly-Gln [SEQ. ID No. 2]

(Netzel-Arnett et al., *Biochemistry 32*, **1993**, 6427-6432)

[0054] Furthermore, in the case of cathepsin B, substrate-specific peptides are known with the sequence

-Gly-Phe-Leu-Gly-

SEQ. ID No. 3

-Gly-Phe-Ala-Leu-

SEQ. ID No. 4

-Ala-Leu-Ala-Leu-

SEQ. ID No. 5

-Arg-Arg- or -Phe-Lys-

Werle, B., Ebert, E., Klein, W., and Spiess, E. (1995), *Biol. Chem. Hoppe-Seyler* 376, 157-164; Ulricht, B., Spiess, E., Schwartz-Albiez, R., and Ebert, W. (1995), *Biol. Chem. Hoppe-Seyler* 376, 404-414).

Please replace paragraph [0055] as follows:

[0055] The peptide sequence that contains intended peptide cleavage points relevant for the target enzyme can also be constructed such that the intended peptide cleavage point is repeated a plurality of times, for example by:

-Gly-Pro-Leu-Gly--Ile-Ala-Gly-Gln-Gly-Pro-Leu-Gly--Ile-Ala-Gly-Gln **SEQ ID No.** 6 or

-Phe-Lys-Phe-L

or a repetitive peptide sequence can be integrated that increases the distance between the thiol-binding group and the relevant intended peptide cleavage point, as for example by:

-(Gly)<sub>n</sub>-Phe-Lys-Phe-Lys- <u>SEQ ID No. 8</u> with, preferably, n = 2 to 20, more preferably  $n \le 12$ .

Please replace paragraph [0084] as follows:

[0084] Here the octapeptide

Gin-Gly-Ala-Ile-Gly-Leu-Pro-Gly SEQ. ID No. 9

derivatized with maleinimidoglycine 1 (Mr 848, prepared by solid-phase synthesis by Bachem AG, Switzerland) was reacted with doxorubicin according to the following method:

[0087] The peptide sequence Gln-Gly-Ala-Ile-Gly-Leu-Pro-Gly SEQ. ID No. 9

is recognized by the matrix metalloprotease MMP 9 and cleaved between isoleucine and glycine. This was shown by the following experiment: 200  $\mu L$  of a 100  $\mu M$ 

solution of HSA-Cys<sup>34</sup>-2 was incubated for 30 minutes at 37 °C with trypsine/aprotinine-activated MMP 9 (2 mU, from Calbiochem, Germany). The liberation of DOXO-Gln-Gly-Ala-Ile due to cleavage with MMP 9 was confirmed by HPLC gel chromatography (Biosil 250 SEC column from Biorad, detection at  $\lambda$  = 495 nm) before incubation (t = 0, compare Fig. 2A) and after an incubation time of 30 minutes with activated MMP 9 (t = 30, compare Fig. 2B).

At the Examiner's request, Applicant is supplying a clear copy of the structure at the top of page 25 (attached at end of this paper).